Our clinical education benefits continue to grow

We offer you the updated resources you need to stay current on clinical and quality advances that optimize patient care.

AAD Clinical Community

Last year, we launched the AAD Clinical Community — a free, secure forum by dermatologists for dermatologists to discuss clinical issues and more. The forum is safe, organized, and moderated, and is free to members of the Academy. It’s also popular!

• 8 out of 10 AAD members engaged* with the AAD Clinical Community at least once every 90 days in 2022, discussing clinical cases and research.

• Number of members onboarded: 20,913

• Number of engaged* members: Nearly 17,000

• Average unique views per discussion: 2,400+

• Average responses per discussion: 10

As we were developing this member offering, your online security was top of mind. By having our AAD Clinical Community hosted by DocMatter, we are assured of the highest standard of data privacy. They are compliant with two of the strictest digital privacy laws — the California Consumer Privacy Action (CCPA) and the European General Data Protection Regulation (GDPR) — for all members, not just those in California and Europe. In addition, participating members own their own data, content, and submissions. Your intellectual property is yours.

Learn more about the AAD Clinical Community.

* An engaged member is defined as any member who reads, responds to, or posts a discussion.

Updated guidelines on actinic keratosis and atopic dermatitis

What is the Academy doing to help physicians advance patient care? A lot, actually:

• In June, the Academy released an update to its Guidelines of Care for the Management of Actinic Keratosis (AK) to reflect tirbanibulin research. The update, published in JAAD, focuses on the strongly recommended use of tirbanibulin, a first-in-class microtubule inhibitor recently approved by the FDA to treat AKs.

• The Academy also recently published updated Guidelines of Care for the Management of Atopic Dermatitis in Adults with Topical Therapies in JAAD. These are the second in a series of revised guidelines the AAD is producing on the condition.

These new guidelines, along with others, help you meet your clinical and quality goals. Check out the complete AAD Clinical Guidelines at www.aad.org/guidelines.

JAAD: Number one again!

JAAD achieved the number one Journal Impact Factor (JIF) again in 2022 for the third year in a row, and that’s a big deal! It means that JAAD is being cited more than any other dermatology journal, which may also mean your research is being cited a lot more.

The JIF came in at an all-time high at 15.487 for 2022. JAAD also achieved the greatest number of citations in the field — 41,522. Both measures place JAAD resoundingly in the No. 1 position in the field of 68 journals measured by Clarivate’s Journal Citations Report (JCR) Web of Science for the two-year window measured.

DermWorld resources at your fingertips

In 2022, we also added more clinical content to DermWorld columns and features. They are archived so that you never miss critical, important content. Don’t miss the columns your colleagues deem their most favored at www.aad.org/dw:

• What’s Hot

• DermWorld Insights & Inquiries

• Clinical Applications

Check out archives of DermWorld Insights and Inquiries.

Readying residents for the future

In addition to adding many new free Boards Fodder study charts for residents via the free DermWorld Directions in Residency publication, we expanded our library of Clinical Pearls for residents. Here’s what we added in 2022:

• Atopic dermatitis

• Scar revision

• Patch tests

• Infantile hemangioma